Lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy in the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, researchers report at the 50th annual meeting of the American Society of Clinical Oncology (ASCO)/a. MULTIMEDIA ALERT: Video and audio are available for download on the Mayo Clinic News Network/a. Results of the phase III clinical ...
Read More
You have just read an article categorized health
titled Single Agent Remains the Gold Standard, ALTTO Test of Dual HER2 Blockade Reveals.
Written by:
editor -
Sunday, June 1, 2014
There are currently no comments for "Single Agent Remains the Gold Standard, ALTTO Test of Dual HER2 Blockade Reveals"
Post a Comment